Filing summary
Important identification discrepancy: The request metadata identifies TENAX THERAPEUTICS, INC. and 2012 Q2, but the supplied filing is for Oxygen Biotherapeutics, Inc., for the quarter and six months ended October 31, 2013 (fiscal 2014 Q2). The summary below reflects the supplied filing.
Business context and reporting period
Oxygen Biotherapeutics was a development-stage specialty pharmaceutical company focused on critical-care products. Its programs included Oxycyte, in Phase II-B studies for severe traumatic brain injury, and levosimendan, acquired after quarter-end for development in cardiac-surgery patients at risk of low cardiac output syndrome. Dermacyte generated limited product sales; the company reported no approved drug products for sale.
Financial performance and liquidity
| Metric | Three months ended Oct. 31, 2013 | Three months ended Oct. 31, 2012 | Six months ended Oct. 31, 2013 | Six months ended Oct. 31, 2012 |
|---|---|---|---|---|
| Total net revenue | $55,707 | $514,872 | $221,512 | $786,968 |
| Product revenue | $24,685 | $14,571 | $60,079 | $26,028 |
| Government grant revenue | $34,377 | $509,435 | $192,297 | $775,984 |
| Operating expenses | $2,169,970 | $1,197,715 | $3,925,384 | $3,145,252 |
| Operating loss | $2,114,263 | $682,843 | $3,703,872 | $2,358,284 |
| Interest expense | $1,416,856 | $867,524 | $2,072,660 | $2,793,427 |
| Net loss | $3,531,486 | $1,557,278 | $5,776,759 | $5,143,819 |
| Net loss attributable to common stockholders | $6,083,275 | $1,557,278 | $10,422,099 | $5,143,819 |
| Basic loss per share | $(1.23) | $(0.97) | $(2.94) | $(3.30) |
For the quarter, product revenue rose from a small base, primarily due to Dermacyte distribution-agreement license fees. Grant revenue fell sharply because multiple studies had been completed in the prior year. Quarterly gross margin on product revenue was reported as 86%, versus 37%; six-month gross margin was 49%, versus 42%. Preferred-stock dividends materially increased losses attributable to common stockholders: $2.6 million for the quarter and $4.6 million for the six-month period.
- Cash and cash equivalents: $2.54 million at October 31, 2013, versus $783,528 at April 30, 2013.
- Current assets/current liabilities: $3.09 million/$1.48 million; reported working capital was $1.62 million.
- Cash flow for the six months: $3.58 million used in operations, $68,867 used in investing, and $5.40 million provided by financing. Operating cash use increased from $2.74 million in the prior-year period.
- Debt: $233,324 of current notes payable, net, and no long-term notes payable at October 31. In August, $4.6 million of note principal was exchanged for Series D preferred stock; the company recorded significant noncash interest expense related to debt discount recognition.
- Equity: Stockholders’ equity was $2.85 million, compared with a $1.78 million deficit at April 30. Accumulated development-stage deficit was $122.8 million.
Material changes, outlook, and risks
- In November 2013, after quarter-end, the company acquired certain Phyxius Pharma assets, including exclusive U.S. and Canadian rights to develop and commercialize levosimendan. Consideration was reported at $24.05 million, comprising common stock valued at $8.75 million and Series E preferred stock valued at $15.30 million; the valuations were provisional. The acquisition accounting included $22.0 million of in-process R&D and $3.30 million of goodwill.
- Management said warrant exercises after quarter-end generated approximately $6.2 million in net proceeds and believed available capital would fund operations through June 30, 2014. The filing also states that continued development beyond that date depends on licensing income or additional financing.
- Management planned a levosimendan Phase III trial at approximately 50 North American centers, targeting 760 patients, with enrollment expected to begin in the third quarter of 2014 and take about 18 months. Oxycyte Phase II-B TBI work was ongoing. These were forward-looking plans, not guaranteed outcomes.
- The filing reports substantial doubt about the company’s ability to continue as a going concern. It had recurring losses, required substantial additional capital, and warned that financing might not be available on acceptable terms or at all, potentially forcing delays or reductions to development programs.
- Series C and D preferred shares carried 8% dividends, conversion and make-whole provisions, and were accompanied by substantial warrants. The filing disclosed significant potential dilution from outstanding convertible and exercisable securities. A director was also the investment manager of a fund holding Series D securities and warrants.
- Other key risks included clinical-trial and regulatory uncertainty, reliance on third-party manufacturers, commercialization and reimbursement challenges, and Nasdaq continued-listing uncertainty. Management stated disclosure controls were effective; no legal proceedings were reported.
Most important facts for investors to verify
- Confirm that this Oxygen Biotherapeutics filing—not a TENAX filing—is the intended document and that the relevant period is fiscal 2014 Q2, not 2012 Q2.
- Check subsequent cash balances and financing against management’s June 30, 2014 runway estimate, including the timing and net proceeds of warrant exercises and the required $1 million Orion license payment.
- Verify the final acquisition valuations, stockholder approvals, vesting conditions, and any remaining consideration or obligations associated with the Phyxius/levosimendan transaction.
- Track actual enrollment, timing, cost, and regulatory progress for the planned levosimendan Phase III trial and the Oxycyte TBI program.
- Assess potential dilution and preferred-stock obligations by reviewing conversion terms, warrants, dividend payments, and the securities outstanding after subsequent events.